Incyte Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Incyte Corp 公司

Incyte Corporation 是一家生物製藥公司，專注於發現、開發和商業化治療藥物。該公司在兩個治療領域開展業務。一個治療領域是血液學/腫瘤學，包括骨髓增生性腫瘤和移植物抗宿主病，以及實體瘤和血液系統惡性腫瘤。其另一個治療領域是炎症和自身免疫，包括其皮膚病商業特許經營權。其血液學和腫瘤學特許經營權包括六種產品，即 JAKAFI (ruxolitinib)、MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab)、PEMAZYRE (pemigatinib)、ICLUSIG (ponatinib)、NIKTIMVO (axatilimab-csfr) 和 ZYNYZ (retifanlimab-dlwr)，以及衆多臨牀開發項目。該公司的產品線還包括兩種一流的 Mas 相關 G 蛋白偶聯受體（MRGPRX2）小分子拮抗劑和口服 MRGPRX4 拮抗劑 INCB000547。

Incyte Corp簡介



公司代碼INCY

公司名稱Incyte Corp

上市日期Dec 06, 1993

CEOMr. Bill Meury

員工數量2617

證券類型Ordinary Share

年結日Dec 06

公司地址1801 Augustine Cut-Off

城市WILMINGTON

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編19803

電話13024986700

網址https://www.incyte.com/

公司代碼INCY

上市日期Dec 06, 1993

CEOMr. Bill Meury

Incyte Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

--

Mr. Paul J. Clancy

Independent Director

147.17K

+0.19%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Mr. Michael James Morrissey

Executive Vice President, Head - Global Technical Operations

86.16K

+5.70%

Dr. Katherine A. High, M.D.

Independent Director

66.08K

+3.96%

Dr. Otis W. Brawley, M.D.

Independent Director

50.10K

+5.29%

Dr. Susanne Schaffert, Ph.D.

Independent Director

37.95K

+4.60%

Dr. Pablo J. Cagnoni

President - Research and Development

35.48K

+62.39%

Mr. Lee Heeson

Executive Vice President - Incyte, International

32.31K

-1.41%

名稱

名稱/職務

職務

持股

持股變動

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

--

Mr. Paul J. Clancy

Independent Director

147.17K

+0.19%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Mr. Michael James Morrissey

Executive Vice President, Head - Global Technical Operations

86.16K

+5.70%

Dr. Katherine A. High, M.D.

Independent Director

66.08K

+3.96%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

JAKAFI revenues

763.79M

62.84%

OPZELURA revenues

164.50M

13.53%

JAKAVI product royalty revenues

109.71M

9.03%

NIKTIMVO revenues

36.15M

2.97%

OLUMIANT product royalty revenues

33.48M

2.75%

其他

107.89M

8.88%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

JAKAFI revenues

763.79M

62.84%

OPZELURA revenues

164.50M

13.53%

JAKAVI product royalty revenues

109.71M

9.03%

NIKTIMVO revenues

36.15M

2.97%

OLUMIANT product royalty revenues

33.48M

2.75%

其他

107.89M

8.88%

股東統計

更新時間: 10月22日週三

持股股東

股東類型

持股股東

佔比

Baker Bros. Advisors LP

15.66%

The Vanguard Group, Inc.

10.21%

Dodge & Cox

7.43%

BlackRock Institutional Trust Company, N.A.

5.95%

State Street Investment Management (US)

5.03%

其他

55.71%

持股股東

佔比

Baker Bros. Advisors LP

15.66%

The Vanguard Group, Inc.

10.21%

Dodge & Cox

7.43%

BlackRock Institutional Trust Company, N.A.

5.95%

State Street Investment Management (US)

5.03%

其他

55.71%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

38.63%

Investment Advisor

37.21%

Hedge Fund

20.76%

Pension Fund

2.95%

Individual Investor

2.17%

Research Firm

2.06%

Bank and Trust

1.47%

Sovereign Wealth Fund

0.77%

Family Office

0.29%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1419

203.92M

103.87%

-180.79K

2025Q2

1423

201.60M

103.23%

-197.50K

2025Q1

1457

199.01M

102.81%

-12.15M

2024Q4

1448

191.80M

99.11%

-19.23M

2024Q3

1401

192.85M

100.02%

-35.92M

2024Q2

1385

209.06M

108.78%

-39.98M

2024Q1

1357

227.85M

101.54%

-21.15M

2023Q4

1323

228.89M

102.19%

-14.49M

2023Q3

1300

224.25M

100.13%

-17.63M

2023Q2

1306

220.30M

98.76%

-17.67M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Baker Bros. Advisors LP

30.74M

15.74%

+256.17K

+0.84%

Jun 30, 2025

The Vanguard Group, Inc.

20.05M

10.27%

+134.71K

+0.68%

Jun 30, 2025

Dodge & Cox

14.60M

7.47%

-269.15K

-1.81%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

11.69M

5.99%

-228.50K

-1.92%

Jun 30, 2025

State Street Investment Management (US)

9.88M

5.06%

-159.70K

-1.59%

Jun 30, 2025

AQR Capital Management, LLC

8.20M

4.2%

+1.47M

+21.75%

Jun 30, 2025

Geode Capital Management, L.L.C.

4.35M

2.23%

+139.74K

+3.32%

Jun 30, 2025

Renaissance Technologies LLC

3.88M

1.99%

+173.20K

+4.67%

Jun 30, 2025

LSV Asset Management

3.86M

1.98%

+223.86K

+6.15%

Jun 30, 2025

Invesco Capital Management LLC

2.96M

1.52%

+218.65K

+7.97%

Jun 30, 2025

持股ETF



更新時間: 10月6日週一

機構名稱

佔比

iShares Genomics Immunology and Healthcare ETF

4.92%

First Trust NYSE Arca Biotechnology Index Fund

4%

Invesco Biotechnology & Genome ETF

3.34%

SPDR S&P Biotech ETF

2.86%

VanEck Biotech ETF

2.39%

Bushido Capital US Equity ETF

2.34%

Strategas Global Policy Opportunities ETF

2.31%

Innovator IBD Breakout Opportunities ETF

2.2%

Virtus LifeSci Biotech Products ETF

2.04%

Invesco S&P 500 Equal Weight Health Care ETF

2.02%

iShares Genomics Immunology and Healthcare ETF

佔比4.92%

First Trust NYSE Arca Biotechnology Index Fund

佔比4%

Invesco Biotechnology & Genome ETF

佔比3.34%

SPDR S&P Biotech ETF

佔比2.86%

VanEck Biotech ETF

佔比2.39%

Bushido Capital US Equity ETF

佔比2.34%

Strategas Global Policy Opportunities ETF

佔比2.31%

Innovator IBD Breakout Opportunities ETF

佔比2.2%

Virtus LifeSci Biotech Products ETF

佔比2.04%

Invesco S&P 500 Equal Weight Health Care ETF

佔比2.02%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據